Drugs / Tilavonemab
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03413319 | Apr 2018 → Nov 2019 | progressive supranuclear palsy | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT02494024 | Jul 2015 → Aug 2016 | progressive supranuclear palsy | C2N Diagnostics | Completed | No outcome recorded |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT03712787 | Mar 2019 → Sep 2021 | Alzheimer disease | AbbVie | Terminated | No outcome recorded |
| Phase 2 | NCT03391765 | Jan 2018 → Dec 2019 | progressive supranuclear palsy | AbbVie | Terminated | No outcome recorded |
| Phase 2 | NCT02880956 | Jan 2017 → Mar 2021 | Alzheimer disease | AbbVie | Completed | Missed primary |
| Phase 2 | NCT02985879 | Dec 2016 → Nov 2019 | progressive supranuclear palsy | AbbVie | Terminated | Missed primary |
| Comparator or background therapy1 trial | ||||||
| — | NCT03744546 Background | — | corticobasal degeneration disorder | AbbVie | No longer available | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-07-17 | AbbVie | Regulatory C2N and AbbVie Announce FDA Orphan Drug Designation of C2N-8E12 (ABBV-8E12) for the Treatment of Progressive Supranuclear Palsy abbvie.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has granted their investigational recombinant humanized anti-tau antibody, C 2 N-8E12 (ABBV-8E12), an orphan drug designation for the treatment of progressive supranuclear palsy (PSP). |
All press releases naming this drug 2 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tilavonemab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03712787 ↗ |
| Known as | ABBV-8E12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02880956 ↗ |
| Known as | C2N-8E12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02494024 ↗ |
| Action | Inhibit | “Microtubule-associated protein tau inhibitor” CHEMBL4297860 ↗ |
| Modality | Monoclonal antibody | “C2N-8E12 is a humanized recombinant anti-human tau antibody.” NCT02494024 ↗ |
| Route | Intravenous | “single intravenous (IV) infusion of C2N-8E12” NCT02494024 ↗ |
| Target | MAPT | “Microtubule-associated protein tau inhibitor” CHEMBL4297860 ↗ |